Nirmatrelvir–Ritonavir and Viral Load Rebound in Covid-19
Nirmatrelvir–Ritonavir and Viral Load Rebound in Covid-19
About this item
Full title
Nirmatrelvir–Ritonavir and Viral Load Rebound in Covid-19
Author / Creator
Publisher
Boston: Massachusetts Medical Society
Journal title
The New England journal of medicine, 2022-09, Vol.387 (11), p.1047-1049
Language
English
Formats
Publication information
Publisher
Boston: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Cases of SARS-CoV-2 viral load rebound have been reported after a 5-day course of nirmatrelvir–ritonavir. Investigators evaluating viral load rebound among high-risk patients found similar results with nirmatrelvir–ritonavir and placebo.
Alternative Titles
Full title
Nirmatrelvir–Ritonavir and Viral Load Rebound in Covid-19
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9513855
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9513855
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMc2205944
How to access this item
Log in as a Library member
